Demand for Peripherally Inserted Central Catheter in UK (2026 - 2036)

Peripherally Inserted Central Catheter Outlook in the UK 2026 to 2036

Demand for peripherally inserted central catheters in the UK is projected to be valued at USD 119.2 million in 2026 and is expected to reach USD 157.7 million by 2036, expanding at a 2.8% CAGR. This trajectory is defined by clinical decisions within NHS trusts and private healthcare facilities seeking reliable, cost-effective vascular access for medium to long-term therapies. The adoption curve is shaped by daily patient care protocols, infection control standards, and the strategic planning of infusion services across acute and community settings.

PICC lines are deployed in environments where catheter dwell time, complication rates, and patient comfort directly influence clinical outcomes and departmental efficiency. Procurement teams judge performance through reductions in catheter-related bloodstream infections, improved first-insertion success rates, material biocompatibility, and the device’s ability to withstand specific therapeutic regimens. Clinical leads prioritize products that enhance insertion safety, minimize maintenance interventions, and support a broad range of infusion protocols.

For clinical procurement specialists and vascular access teams, the evaluation extends beyond the catheter itself. Decisions are intrinsically linked to insertion kit compatibility, securement and dressing solutions, clinician training requirements, and the manufacturer’s support for clinical guidelines.

The ability to standardize products across hospital networks, train staff efficiently on insertion techniques, and access reliable clinical evidence supports adoption across large teaching hospitals and smaller community units alike.

Quick Stats for Peripherally Inserted Central Catheter Demand in the UK

• Peripherally Inserted Central Catheter Valuation in the UK (2026): USD 119.2 million
• Peripherally Inserted Central Catheter Forecast Valuation in the UK (2036): USD 157.7 million
• Peripherally Inserted Central Catheter Forecast CAGR 2026 to 2036: 2.8%
• Leading Regional Growth: England (3.1%)
• Leading Product: Conventional PICC (40.6% share)
• Leading Lumen: Single Lumen (52.0% share)
• Leading Application: Chemotherapy (34.7% share)
• Leading End User: Hospitals (33.0% share)
• Key Companies Profiled: Becton, Dickinson and Company (BD); Cardinal Health Inc.; AngioDynamics, Inc.; Teleflex Incorporated; Vygon Group

 

Peripherally Inserted Central Catheter Industry in the UK Key Takeaways

Metric	Value
Industry Value (2026)	USD 119.2 million
Industry Forecast Value (2036)	USD 157.7 million
Forecast CAGR 2026 to 2036	2.8%

Why is the UK Building Steady Demand for Peripherally Inserted Central Catheters?

Demand in the UK grows as healthcare providers intensify focus on patient safety, therapy delivery efficiency, and the shift of care into community settings. Hospitals face pressure to reduce repeated peripheral cannulations, lower the risk of phlebitis, and provide stable venous access for complex drug regimens. A reliable PICC line supports timely administration of therapies, protects peripheral vasculature, and can facilitate earlier patient discharge with ongoing infusion needs.

Clinical practice evolution and demographic trends influence procurement cycles. An ageing population and increasing prevalence of conditions requiring long-term intravenous therapy underpin steady demand. In this environment, vascular access teams focus on devices that minimize insertion complications, offer proven material safety, and align with UK guidelines on vascular access device management.

Therapy-specific requirements also guide product selection. Oncology units administering vesicant chemotherapy agents prioritize catheters with confirmed compatibility and tip location accuracy. Teams managing patients requiring parenteral nutrition evaluate lumen design and infection risk profiles.

Many procurement teams also cross-reference PICC selections against options for implantable port systems used in long-term oncology care when determining the most appropriate vascular access strategy for a patient’s full treatment pathway.

Procurement decisions are shaped by safety and cost-containment objectives. Emphasis on reducing healthcare-associated infections directs buyers toward products with antimicrobial technologies and securement systems designed to minimize microbial migration.

This pushes clinical buyers to value designs supported by strong clinical outcome data, comprehensive insertion training programs, and a total cost-of-care rationale that accounts for potential complication-related expenses.

How is Peripherally Inserted Central Catheter Demand Segmented by Product, Lumen, Application, and End User?

The segmentation of the PICC landscape in the UK reflects how clinical teams match device characteristics to specific therapeutic needs, patient populations, and care settings.

What sustains the predominant position of conventional PICC lines in clinical inventory?

Conventional PICC lines hold a 40.6% share as the leading product type. This reflects their established role as a versatile, cost-effective solution for a wide array of intravenous therapies requiring secure central access. For hospital procurement, these devices represent a reliable standard of care with which clinical staff have extensive familiarity, supporting consistent insertion and maintenance protocols across diverse departments.

Their sustained use is often seen in settings where power-injection capability is not a routine requirement for the patient population. Evaluation of these devices frequently connects to broader procurement strategies for vascular access devices that improve patient comfort.

Why does single-lumen design remain the most frequently selected configuration?

Single lumen PICCs account for a 52.0% share, indicating that a majority of clinical requirements are for single-therapy infusion or intermittent medication delivery. This configuration is often selected for its lower infection risk profile relative to multi-lumen devices, simpler maintenance, and smaller catheter diameter, which can be beneficial for patient vasculature.

This segment fits a high volume of patients receiving extended antibiotic courses, hydration therapy, or specific chemotherapy regimens not requiring concurrent infusion. The choice of lumen number is a fundamental part of clinical decision-making for intravenous drug delivery systems.

What cements Chemotherapy as the Leading Application driving PICC Utilization?

Chemotherapy represents a 34.7% share as the leading application. The mandatory need for secure, reliable venous access for often prolonged and frequent cycles of vesicant or irritant drugs makes PICCs a cornerstone of oncology care. The primary clinical driver is patient safety, ensuring cytotoxic agents are delivered centrally to minimize tissue damage and extravasation risk.

Oncology teams prioritize catheter designs with strong evidence for chemical compatibility and mechanical stability. This application area is closely linked to technologies for safe drug delivery in oncology settings.

What establishes hospitals as the core end-user segment for PICC procurement?

Hospitals represent a 33.0% share as the leading end-user segment. Acute care settings are where the majority of PICC insertions occur, driven by inpatient initiation of long-term therapies, management of complex infections, and perioperative nutritional support.

High-volume purchasing, stringent tendering processes, and a requirement for products that integrate seamlessly with existing insertion protocols and ward-based care characterize hospital procurement. Investment in hospital PICCs is frequently evaluated alongside needs for complementary infusion pump technology to ensure a fully compatible therapy delivery ecosystem.

What are the Dynamics, Restraints, Opportunities, and Threats Shaping this Space?

What Dynamics maintain Consistent Procurement Activity across NHS and private healthcare?

Patient safety and service efficiency are primary drivers. Clinical governance leads demand devices with low thrombosis and infection rates. Procurement teams seek products that simplify inventory and standardize care pathways. Finance departments evaluate total treatment cost, favoring devices that reduce complication-related expenditures.

Vascular access nurses prioritize products that enhance insertion success and patient comfort. Regulatory compliance remains a constant dynamic, with adherence to Medicines and Healthcare products Regulatory Agency (MHRA) regulations underpinning procurement safety standards.

What restraints can slow the adoption of advanced or newer PICC technologies?

Budgetary constraints within NHS trusts create a significant barrier, often favoring familiar, cost-led products over premium-priced alternatives with advanced features. Clinical inertia and the need for comprehensive re-training on new insertion techniques for different device designs can delay uptake.

The complexity of demonstrating clear cost-benefit superiority in real-world settings can hinder adoption. Procurement is heavily influenced by the need for robust clinical evidence and health economic analysis before switching established product portfolios.

Where are the strongest opportunities for device manufacturers and clinical educators?

Differentiation through clinical evidence and service is a major opportunity. Manufacturers that provide comprehensive outcome data, hands-on simulation training for inserters, and dedicated clinical support specialists build loyal adoption.

Another opportunity exists in developing integrated solutions that bundle the catheter with ultrasound-guided insertion systems and securement/dressing products to improve overall procedure success and durability. Growth in community-based care presents an opportunity for designs facilitating easier patient self-care or community nurse management.

What threats can affect anticipated demand growth?

Competition from alternative vascular access devices such as midline catheters for shorter-term needs or totally implantable ports for very long-term therapy, can segment demand. Significant downward pressure on healthcare procurement budgets can freeze or slow device upgrades.

Any high-profile safety concerns or product recalls related to catheter materials or design can severely damage trust in a specific brand or technology, shifting demand rapidly. This reinforces the critical importance of post-market surveillance and transparent incident reporting.

How is Peripherally Inserted Central Catheter Demand Evolving across Key Regions in the UK?

Regional adoption varies based on the concentration of specialist clinical services, oncology center locations, demographic health needs, and the maturity of community-based IV therapy programs.

Region	CAGR 2026 to 2036
England	3.1%
Scotland	2.8%
Wales	2.6%
Northern Ireland	2.3%

How does England’s Concentration of Specialist Tertiary Care Drive leading Adoption Rates?

England grows at 3.1%, supported by its high density of major oncology centers, large teaching hospitals with active vascular access teams, and well-established ambulatory care pathways. Larger procurement frameworks and greater access to clinical specialist training foster confidence in adopting and standardizing devices. The scale of patient volume encourages investment in products that improve efficiency and reduce variation across regional networks.

What factors underpin Scotland’s steady demand focused on clinical outcomes and remote care?

Scotland expands at 2.8%, shaped by its integrated national health service structure and the need to deliver complex care across geographically dispersed populations. Procurement decisions often emphasize product reliability, strong clinical evidence, and designs that are suitable for use in both central hospitals and more remote community settings, supporting patient management closer to home.

How is Wales advancing adoption through integrated health board procurement and pathway development?

Wales grows at 2.6%, driven by health board-level procurement strategies that aim to standardize care. There is a focus on selecting devices that balance clinical performance with cost-effectiveness, supporting predictable budgeting across acute and community services. Adoption is linked to the development of unified clinical guidelines for vascular access.

Why does Northern Ireland exhibit a steady, value-conscious adoption pathway?

Northern Ireland rises at 2.3%, reflecting a careful, evidence-based approach within its integrated health and social care system. Procurement teams frequently prioritize products with a strong proven track record, clear benefits for patient safety, and reliable supplier support for training and clinical queries, ensuring sustainable implementation within existing care structures.

What Defines the Competitive Landscape for Peripherally Inserted Central Catheters in the UK?

Clinical evidence, product reliability, strength of clinical education programs, and the depth of technical support shape competition. Consumers evaluate suppliers on practical factors such as catheter material safety data, insertion success rates supported by real-world evidence, compatibility with a wide range of therapeutics, and the vendor’s ability to support continuous clinical training.

Becton, Dickinson and Company (BD) is associated with a comprehensive vascular access portfolio and strong emphasis on clinical education and procedural safety. Cardinal Health Inc. competes through a broad range of medical device offerings, including PICCs designed for clinical efficiency and patient comfort. AngioDynamics, Inc. is positioned with specialized vascular access and interventional products, often featuring advanced material technologies.

Teleflex Incorporated provides a wide array of PICCs, including power-injectable models, supported by procedural kits and educational resources. Vygon Group contributes to the landscape with a focus on specialized catheters, including neonatal PICCs, catering to specific patient population needs.

Key Industry Participants

• Becton, Dickinson and Company (BD)
• Cardinal Health Inc.
• AngioDynamics, Inc.
• Teleflex Incorporated
• Vygon Group

Scope of Report

Items	Values
Quantitative Units	USD Million
Product	Conventional PICC; Power Injected PICC; Neonatal PICC
Lumen	Single Lumen; Double Lumen; Multiple Lumen
Application	Chemotherapy; Long-term IV Infusion; Parenteral Nutrition; Blood Transfusion; Difficult Intravenous Access
End User	Hospitals; Cancer Research Institutes; Long Term Care Centers; Independent Infusion Centers; Ambulatory Surgical Center
Regions Covered	England; Scotland; Wales; Northern Ireland
Key Companies Profiled	Becton, Dickinson and Company (BD); Cardinal Health Inc.; AngioDynamics, Inc.; Teleflex Incorporated; Vygon Group

Peripherally Inserted Central Catheter Demand in the UK by Segments

By Product

• Conventional PICC
• Power Injected PICC
• Neonatal PICC

By Lumen

• Single Lumen
• Double Lumen
• Multiple Lumen

By Application

• Chemotherapy
• Long-term IV Infusion
• Parenteral Nutrition
• Blood Transfusion
• Difficult Intravenous Access

By End User

• Hospitals
• Cancer Research Institutes
• Long Term Care Centers
• Independent Infusion Centers
• Ambulatory Surgical Center

By Region

• England
• Scotland
• Wales
• Northern Ireland

Bibliography

• Department of Health. (2016). Health Technical Memorandum 07-01: Safe management of healthcare waste. UK Government.
• Medicines and Healthcare products Regulatory Agency. (2021). Medical devices: conformity assessment and the UKCA mark. MHRA.
• National Institute for Health and Care Excellence. (2012). Infection: prevention and control of healthcare-associated infections in primary and community care (CG139). NICE.
• NHS England. (2021). NHS Standard Contract for Vascular Access Services. NHS England.
• Royal College of Nursing. (2021). Standards for infusion therapy. RCN.